YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts

Published:2007-09-01 Issue:17 Volume:67 Page:8014-8021
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Nakahara Takahito,Takeuchi Masahiro,Kinoyama Isao,Minematsu Tsuyoshi,Shirasuna Kenna,Matsuhisa Akira,Kita Aya,Tominaga Fumiko,Yamanaka Kentaro,Kudoh Masafumi,Sasamata Masao

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 423 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bivalent chromatin accommodates survivin and BRG1/SWI complex to activate DNA damage response in CD4+ cells;Cell Communication and Signaling;2024-09-11

2. Molecular Insights into the Anticancer Activity of Withaferin-A: The Inhibition of Survivin Signaling;Cancers;2024-09-05

3. SIRT6 suppresses colon cancer growth by inducing apoptosis and autophagy through transcriptionally down-regulating Survivin;Mitochondrion;2024-09

4. Identification and targeting of metastatic biomarkers for hepatocellular carcinoma therapeutics using small molecules library of curcumin analogues;Molecular Diversity;2024-04-30

5. Opposing Interplay between Nuclear Factor Erythroid 2-Related Factor 2 and Forkhead BoxO 1/3 is Responsible for Sepantronium Bromide’s Poor Efficacy and Resistance in Cancer cells: Opportunity for Combination Therapy in Triple Negative Breast Cancer;ACS Pharmacology & Translational Science;2024-04-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP